INmune Bio, Inc.
INMB
$7.28
-$0.04-0.55%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -42.08M | -41.27M | -37.74M | -34.50M | -30.01M |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | 79.00K | 118.00K | 157.00K | 191.00K | 224.00K |
Total Other Non-Cash Items | 7.61M | 7.73M | 7.90M | 7.41M | 7.37M |
Change in Net Operating Assets | 1.04M | 7.68M | 6.66M | 8.58M | 10.44M |
Cash from Operations | -33.36M | -25.75M | -23.03M | -18.32M | -11.98M |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | -- | -- | -- | -- |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -10.00M | -10.00M | -10.00M | -7.50M | -5.00M |
Issuance of Common Stock | 28.21M | 27.79M | 16.27M | 775.00K | 775.00K |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 18.21M | 17.79M | 6.27M | -6.73M | -4.23M |
Foreign Exchange rate Adjustments | 224.00K | -301.00K | -1.00K | 39.00K | -100.00K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -14.93M | -8.26M | -16.76M | -25.00M | -16.31M |